More Publications by © Chronicle Companies

n+p.PNG
Advertise with Derm.city
Chronicle Companies
Terms of Use Policy
Order "To Heal the Skin"

© Chronicle Companies 2018

Powered by Skin Chronicle International

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle
  • Home

  • Skin Chronicle

  • Primers for your Patient

  • Skin Spectrum Summit

  • Chronicle

  • Contact

  • More...

    Skin Cancer

    Improved method for tracking severity and potential spread of melanoma

    January 13, 2016

    A blood test that monitors blood levels of DNA fragments from dead cancer cells does a better job than the current standard test at tracking the severity and potential spread of metastatic melanoma, according to a study published in the journal Molecular Oncology (Jan. 2016; 10(1):157-165).

     

    The standard test, in widespread use for decades to inform treatment decisions, measures blood levels of the enzyme lactate dehydrogenase (LDH). Levels of the enzyme tend to spike during aggressive tumor growth, but are also known to rise as part of other diseases and biological functions. The alternative test looks at levels of circulating tumor DNA (ctDNA) released into the blood when tumor cells die and break apart to spill their contents.

     

    The NYU Langone Medical Center, New York City, team found that ctDNA levels in blood were elevated in 12 of 15 (80%) patients who were about to undergo treatment for their metastatic melanoma. By contrast, blood levels of LDH were elevated before therapy in seven of 23 patients (30%). Results also showed that ctDNA could detect cancer recurrence, as confirmed by X-ray or CT scan, in 22 of 26 (85%) patients tested and undergoing therapy, while LDH was elevated in only 14 patients (54%).

     

    “Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma,” said senior study investigator Dr. David Polsky, The Alfred W. Kopf, M.D. Professor of Dermatologic Oncology at NYU Langone, in a press release.

     

    According to Dr. Polsky, an accurate blood test is preferred by doctors and many patients because it avoids the risk of infection and pain that accompany invasive needle biopsy and the radiation exposure that comes with X-ray or CT scans.

     

    Thirty-one patients with inoperable metastatic melanoma were involved in the study, which took three years to complete. All had one of the two most common genetic mutations linked to the frequently fatal skin cancer, BRAF or NRAS. All had ctDNA and LDH blood tests performed after therapy, and most before treatment at NYU Langone. Normal blood levels of ctDNA were statistically determined by averaging results from 30 people who did not have melanoma.

     

    Dr. Polsky said the growing number of immunological and targeted therapies for metastatic melanoma highlight the urgent need among cancer specialists for a simple but more accurate blood test to monitor the disease. Such a test would help to determine as early as possible when switching to an alternative therapy is warranted.

     

    “A reliable blood test for tracking potential disease progression is preferred because blood tests offer feedback on what is happening throughout the body, while scans may not always visualize all parts of the body,” he said.

     

    Among the study’s other key findings, noted Dr. Polsky, was that the ctDNA test was helpful in patients with small tumors whose melanoma had nevertheless spread. Specifically, ctDNA blood levels were elevated in five of seven such cases, while LDH levels were elevated in only one of 13.

    Please reload

    Featured Posts

    Epigenome a potential target for psoriasis Tx

    December 13, 2019

    New guidelines for rare and dangerous skin tumor

    December 11, 2019

    Reconsider gifting at-home beauty devices this holiday season

    December 9, 2019

    High-dose brachytherapy for BCC, SCC in older patients

    December 6, 2019

    Study: Makeup Products May Harbor Dangerous Bacteria

    December 4, 2019

    Newborn's immune system detects harmful skin bacteria

    December 2, 2019

    Topical rapamycin may slow skin aging

    November 29, 2019

    Statin medications may leave patients vulnerable to skin infections

    November 27, 2019

    Genes show how much sun exposure could lead to melanoma

    November 25, 2019

    Atopic eczema increases fracture risk

    November 22, 2019

    Please reload

    Archive

    December 2019 (6)

    November 2019 (11)

    October 2019 (11)

    September 2019 (13)

    August 2019 (13)

    July 2019 (12)

    June 2019 (11)

    May 2019 (17)

    April 2019 (15)

    March 2019 (13)

    February 2019 (11)

    January 2019 (13)

    December 2018 (12)

    November 2018 (13)

    October 2018 (14)

    September 2018 (9)

    August 2018 (9)

    July 2018 (9)

    June 2018 (13)

    May 2018 (11)

    April 2018 (13)

    March 2018 (13)

    February 2018 (14)

    January 2018 (12)

    December 2017 (6)

    November 2017 (11)

    October 2017 (5)

    September 2017 (4)

    August 2017 (6)

    July 2017 (10)

    June 2017 (12)

    May 2017 (17)

    April 2017 (12)

    March 2017 (19)

    February 2017 (11)

    January 2017 (13)

    December 2016 (11)

    November 2016 (13)

    October 2016 (16)

    September 2016 (16)

    August 2016 (14)

    July 2016 (16)

    June 2016 (16)

    May 2016 (22)

    April 2016 (17)

    March 2016 (15)

    February 2016 (12)

    January 2016 (11)

    December 2015 (13)

    November 2015 (19)

    October 2015 (13)

    September 2015 (15)

    July 2015 (3)

    June 2015 (22)

    March 2015 (3)

    Please reload

    Follow Us
    • Grey Facebook Icon
    • Grey YouTube Icon
    • Grey Instagram Icon
    • Grey Twitter Icon